J
Jeffrey S. Ross
Researcher at State University of New York Upstate Medical University
Publications - 344
Citations - 26516
Jeffrey S. Ross is an academic researcher from State University of New York Upstate Medical University. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 59, co-authored 343 publications receiving 20600 citations. Previous affiliations of Jeffrey S. Ross include Foundation Medicine & State University of New York System.
Papers
More filters
Journal ArticleDOI
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.
Haiyan Xu,Glenn Barnes,Qing Yang,Guo Tan,Daseng Yang,Chieh J. Chou,Jason Sole,Andrew Nichols,Jeffrey S. Ross,Louis A. Tartaglia,Hong Chen +10 more
TL;DR: It is proposed that obesity-related insulin resistance is, at least in part, a chronic inflammatory disease initiated in adipose tissue, and that macrophage-related inflammatory activities may contribute to the pathogenesis of obesity-induced insulin resistance.
Journal ArticleDOI
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers,Caitlin F. Connelly,David Fabrizio,Siraj M. Ali,Riley Ennis,Alexa B. Schrock,Brittany Campbell,Adam Shlien,Juliann Chmielecki,Franklin W. Huang,Yuting He,James Sun,Uri Tabori,Mark Kennedy,Daniel S. Lieber,Steven Roels,Jared White,G. Otto,Jeffrey S. Ross,Levi A. Garraway,Levi A. Garraway,Vincent A. Miller,Phillip J. Stephens,Garrett M. Frampton +23 more
TL;DR: Measurements of TMB from comprehensive genomic profiling are strongly reflective of measurements from whole exome sequencing and model that below 0.5 Mb the variance in measurement increases significantly, demonstrating that many disease types have a substantial portion of patients with high TMB who might benefit from immunotherapy.
Journal ArticleDOI
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis,Michael E. Goldberg,Danielle Greenawalt,Matthew D. Hellmann,Mark M. Awad,Justin F. Gainor,Alexa B. Schrock,Ryan J. Hartmaier,Sally E. Trabucco,Siraj M. Ali,Julia A. Elvin,Gaurav Singal,Jeffrey S. Ross,David Fabrizio,Péter Szabó,Han Chang,Ariella Sasson,Sujaya Srinivasan,Stefan Kirov,Joseph D. Szustakowski,Patrik Vitazka,Robin Edwards,Jose A. Bufill,Neelesh Sharma,Sai-Hong Ignatius Ou,Nir Peled,Nir Peled,David R. Spigel,Hira Rizvi,Elizabeth Jimenez Aguilar,Brett W. Carter,Jeremy J. Erasmus,Darragh Halpenny,Andrew J. Plodkowski,Niamh Long,Mizuki Nishino,Warren Denning,Ana Galan-Cobo,Haifa Hamdi,Taghreed Hirz,Pan Tong,Jing Wang,Jaime Rodriguez-Canales,Pamela Villalobos,Edwin Roger Parra,Neda Kalhor,Lynette M. Sholl,Jennifer L. Sauter,Achim A. Jungbluth,Mari Mino-Kenudson,Roxana Azimi,Yasir Elamin,Jianjun Zhang,Giulia Costanza Leonardi,Fei Jiang,Fei Jiang,Kwok-Kin Wong,J. Jack Lee,Vassiliki A. Papadimitrakopoulou,Ignacio I. Wistuba,Vincent A. Miller,Garrett M. Frampton,Jedd D. Wolchok,Alice T. Shaw,Pasi A. Jänne,Philip J. Stephens,Charles M. Rudin,William J. Geese,Lee A. Albacker,John V. Heymach +69 more
TL;DR: Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets.
Journal ArticleDOI
Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer
Kenneth R. Hess,Keith Anderson,W. Fraser Symmans,Vicente Valero,Nuhad K. Ibrahim,Jaime A. Mejia,Daniel J. Booser,Richard L. Theriault,Aman U. Buzdar,Peter J. Dempsey,Roman Rouzier,Nour Sneige,Jeffrey S. Ross,Tatiana Vidaurre,Henry L. Gomez,Gabriel N. Hortobagyi,Lajos Pusztai +16 more
TL;DR: A 30-probe set pharmacogenomic predictor predicted pCR to T/FAC chemotherapy with high sensitivity and negative predictive value.
Journal ArticleDOI
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors
Garrett M. Frampton,Siraj M. Ali,Margaret Rosenzweig,Juliann Chmielecki,Xinyuan Lu,Todd M. Bauer,Mikhail Akimov,Jose A. Bufill,Carrie B. Lee,David Jentz,Rick Hoover,Sai-Hong Ignatius Ou,Ravi Salgia,Tim Brennan,Zachary R. Chalmers,Savina Jaeger,Alan Huang,Julia A. Elvin,Rachel L. Erlich,Alex Fichtenholtz,Kyle Gowen,Joel R. Greenbowe,Adrienne Johnson,Depinder Khaira,Caitlin McMahon,Eric M. Sanford,Steven Roels,Jared White,Joel Greshock,Robert Schlegel,Doron Lipson,Roman Yelensky,Deborah Morosini,Jeffrey S. Ross,Eric A. Collisson,Malte Peters,Philip J. Stephens,Vincent A. Miller +37 more
TL;DR: Analysis of tumor genomic profiles from 38,028 patients is reported to identify 221 cases with METex14 mutations, including 126 distinct sequence variants, and identify a unique subset of patients likely to derive benefit from MET inhibitors.